Brett Grieb, MD
Hematology & Oncology · Lincoln, NENPI 1740714419
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $569, 2.0 times the $281 reported in 2023. That places this record below the midpoint for hematology & oncology clinicians in NE, where the typical reported total is $3,016.
Across 76 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$194
- AstraZeneca$108
- E.r. Squibb & Sons, L.L.C.$103
- Bristol Myers Squibb$94
- Novartis$86
- Merck$76
- plus $707 from 25 others
What the payments were for
- Food & beverage$1,35199%
- Education$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 12 | $194 |
| AstraZeneca | 5 | $108 |
| E.r. Squibb & Sons, L.L.C. | 6 | $103 |
| Bristol Myers Squibb | 6 | $94 |
| Novartis | 5 | $86 |
| Merck | 4 | $76 |
| Johnson & Johnson | 3 | $74 |
| Sanofi | 3 | $67 |
| Eisai Inc. | 3 | $60 |
| Genmab U.S., Inc. | 3 | $55 |
| AbbVie | 2 | $53 |
| Bayer | 2 | $38 |
| GSK | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Astellas Pharma US Inc | 2 | $30 |
| Servier Pharmaceuticals LLC | 1 | $23 |
| Immunogen, Inc. | 1 | $19 |
| Organon | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| CTI Biopharma Corp. | 1 | $18 |
| AVEO Pharmaceuticals, Inc. | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Adaptive Biotechnologies Corporation | 1 | $15 |
| Medtronic | 1 | $14 |
| Gilead | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $14 |
How this compares
$1,368 in reported general payments places this provider in the 30th percentile of 73 hematology & oncology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 11 | $199,600 |
| Anastrozole | 50 | $676 |
| Dexamethasone | 38 | $454 |
| Fluconazole | 13 | $386 |
| Ondansetron Hcl | 71 | $362 |
| Prochlorperazine Maleate | 47 | $355 |
| Tamoxifen Citrate | 27 | $342 |
| Potassium Chloride | 35 | $301 |
| Acyclovir | 40 | $258 |
| Oxycodone Hcl | 22 | $186 |
| Duloxetine Hcl | 11 | $132 |
| Prednisone | 39 | $105 |
| Gabapentin | 21 | $96 |
| Pantoprazole Sodium | 16 | $73 |
| Levofloxacin | 12 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $94 | $199,60011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 73 hematology & oncology providers in Nebraska.
Other hematology & oncology in Lincoln
- Madhu MidathadaLincoln$24K
- Steven DunderLincoln$20K
- Kailash MosalpuriaLincoln$17K
- Nathan GreenLincoln$10K
- Melissa CetakLincoln$6K
- Eric AveryLincoln$6K
- Wallace PetersonLincoln$5K
- Amanda BauerLincoln$5K
- Joni TilfordLincoln$4K
- Kathleen TonkinLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.